Financial Performance - The company reported a basic earnings per share of -0.1100 yuan for Q1 2025, an improvement of 15.38% compared to -0.1300 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 1.57 billion yuan, representing an 18.94% increase from 1.32 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.14 billion yuan, showing a 17.65% improvement from -0.17 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -0.58%, an improvement of 13.43% compared to -0.67% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 62.2289 million shares, accounting for 50.98% of the circulating shares, with an increase of 2.4569 million shares compared to the previous period [2] - Wuhan Sanjiangyuan Investment Development Co., Ltd. holds 25.2094 million shares, representing 20.65% of the total share capital, with no change [3] - Wuhan Beruile Enterprise Management Co., Ltd. holds 14.7906 million shares, accounting for 12.12% of the total share capital, also unchanged [3] - The new entrant in the top ten shareholders is China Merchants Fund Management Co., Ltd. - Social Security Fund 1903 Portfolio, holding 1.2350 million shares, which accounts for 1.01% [3] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [4]
海特生物:2025一季报净利润-0.14亿 同比增长17.65%